These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 28755091)

  • 1. CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target.
    Holzinger A; Abken H
    Cancer Immunol Immunother; 2017 Nov; 66(11):1505-1507. PubMed ID: 28755091
    [No Abstract]   [Full Text] [Related]  

  • 2. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Armed T cells with CAR for cancer immunotherapy.
    Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):331-2. PubMed ID: 27080712
    [No Abstract]   [Full Text] [Related]  

  • 4. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity.
    Thistlethwaite FC; Gilham DE; Guest RD; Rothwell DG; Pillai M; Burt DJ; Byatte AJ; Kirillova N; Valle JW; Sharma SK; Chester KA; Westwood NB; Halford SER; Nabarro S; Wan S; Austin E; Hawkins RE
    Cancer Immunol Immunother; 2017 Nov; 66(11):1425-1436. PubMed ID: 28660319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strategies to genetically engineer T cells for cancer immunotherapy.
    Spear TT; Nagato K; Nishimura MI
    Cancer Immunol Immunother; 2016 Jun; 65(6):631-49. PubMed ID: 27138532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CARs in the Lead Against Multiple Myeloma.
    Ormhøj M; Bedoya F; Frigault MJ; Maus MV
    Curr Hematol Malig Rep; 2017 Apr; 12(2):119-125. PubMed ID: 28233151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors.
    DeRenzo C; Krenciute G; Gottschalk S
    Am Soc Clin Oncol Educ Book; 2018 May; 38():830-837. PubMed ID: 30231350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric T cells for adoptive immunotherapy of cancer: using what have we learned to plan for the future.
    Peinert S; Kershaw MH; Prince HM
    Immunotherapy; 2009 Nov; 1(6):905-12. PubMed ID: 20635906
    [No Abstract]   [Full Text] [Related]  

  • 9. Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells.
    Davies DM; Maher J
    Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):165-78. PubMed ID: 20373147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing chimeric antigen receptors to effectively and safely target tumors.
    Jensen MC; Riddell SR
    Curr Opin Immunol; 2015 Apr; 33():9-15. PubMed ID: 25621840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Helping CAR T cells reach tumors.
    Cancer Discov; 2015 Jan; 5(1):OF6. PubMed ID: 25583818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-killing CAR therapies gain speed.
    Weber M
    Cancer Discov; 2015 Jan; 5(1):7. PubMed ID: 25583785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
    Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP
    Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishing guidelines for CAR-T cells: challenges and considerations.
    Wang W; Qin DY; Zhang BL; Wei W; Wang YS; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):333-9. PubMed ID: 26965523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?
    Hombach AA; Abken H
    Expert Rev Clin Immunol; 2017 Feb; 13(2):151-155. PubMed ID: 27546707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to improve the clinical performance of chimeric antigen receptor-modified T cells for cancer.
    Zhang Q; Li H; Yang J; Li L; Zhang B; Li J; Zheng J
    Curr Gene Ther; 2013 Feb; 13(1):65-70. PubMed ID: 23256743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.